CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018	[1]
Current assets:
Cash and cash equivalents	$ 172,946	$ 62,417
Short-term marketable securities	124,255	52,491
Related party receivables from collaborative arrangements	69,211	83,286
Prepaid expenses and other current assets	383	849
Total current assets	366,795	199,043
Property and equipment, net	24	160
Capitalized fees paid to a related party, net	142,531	152,899
Deferred tax assets	166,555	196,054
Other assets	48	37
Total assets	675,953	548,193
Current liabilities:
Accounts payable	35	11
Accrued personnel-related expenses	509	470
Accrued interest payable	1,773	4,264
Other accrued liabilities	1,012	955
Total current liabilities	3,329	5,700
Long-term debt, net of discount and issuance costs	388,644	382,855
Other long-term liabilities	217	586
Commitments and contingencies
Stockholders' equity
Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding	0	0
Common stock: $0.01 par value, 200,000 shares authorized, 101,279 and 101,098 issued and outstanding as of September 30, 2019 and December 31, 2018, respectively	1,013	1,011
Additional paid-in capital	1,258,370	1,256,267
Accumulated other comprehensive income (loss)	25	(3)
Accumulated deficit	(992,353)	(1,103,692)
Total Innoviva stockholders' equity	267,055	153,583
Noncontrolling interest	16,708	5,469
Total stockholders' equity	283,763	159,052
Total liabilities and stockholders' equity	$ 675,953	$ 548,193

[1] Condensed consolidated balance sheet as of December 31, 2018 has been derived from audited consolidated financial statements.